ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "patient-reported outcome measures and rheumatoid arthritis (RA)"

  • Abstract Number: 2358 • 2018 ACR/ARHP Annual Meeting

    Risk Factors for Persistent Discordance in Global Assessment of Rheumatoid Arthritis (RA) Disease Activity between RA Patients and Their Physicians: Analysis Based on a Nationwide RA Database (2011 to 2016)

    Tetsuji Sawada1, Susumu Nishiyama2, Mayu Tago3, Koichiro Tahara3, Eri Kato1, Hiroaki Mori3, Haeru Hayashi3, Toshihiro Matsui4, Jinju Nishino5 and Shigeto Tohma6, 1Rheumatology, Tokyo Medical University, Shinjuku Tokyo, Japan, 2Rheumatic Disease Center, Kurashiki Medical Center, Okayama, Japan, 3Rheumatology, Tokyo Medical University, Tokyo, Japan, 4National Hospital Organization Sagamihara l Hospital, Clinical Research Center for Allergy and Rheumatology, Kanagawa, Japan, 5Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, 6National Hospital Organization Tokyo National Hospital, Kiyose, Japan

    Background/Purpose: Discordance between patient global assessment (PGA) and physician global assessment (PhGA) of RA disease activity may be problematic in clinical practice. Previous studies, including…
  • Abstract Number: 2524 • 2018 ACR/ARHP Annual Meeting

    Effect of Upadacitinib on Pain and Morning Stiffness in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs

    Alvin F. Wells1, Yvonne C. Lee2, Namita Tundia3, Jessica Suboticki3, Kun Chen3, Alan Friedman3 and Vibeke Strand4, 1Rheumatology and Immunotherapy Center, Franklin, WI, 2Northwestern University Feinberg School of Medicine, Chicago, IL, 3AbbVie Inc., North Chicago, IL, 4Stanford University, Palo Alto, CA

    Background/Purpose: Although treatment with csDMARDs and bDMARDs can lead to remission in patients with RA, many patients still experience pain and morning (AM) stiffness, which…
  • Abstract Number: 2531 • 2018 ACR/ARHP Annual Meeting

    Assessment of Pain Relief with Baricitinib By Treatment History in Patients with Refractory Rheumatoid Arthritis

    Janet E. Pope1, Amanda Quebe2, Baojin Zhu2, Luna Sun2, Carol L. Gaich2, Francesco de Leonardis2, Anabela Cardoso2 and Mark C. Genovese3, 1St. Joseph's Health Care, Divsion of Rheumatology, London, ON, Canada, 2Eli Lilly and Company, Indianapolis, IN, 3Stanford University Medical Center, Palo Alto, CA

    Background/Purpose:  Baricitinib (BARI) 2 mg and 4 mg once daily demonstrated significant clinical improvements compared to placebo in the phase 3 study of RA patients…
  • Abstract Number: 2547 • 2018 ACR/ARHP Annual Meeting

    Upadacitinib Monotherapy Improves Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate

    Vibeke Strand1, Maya Buch2, Namita Tundia3, Heidi S. Camp3, Jessica Suboticki3, Debbie Goldschmidt4 and Alvin F. Wells5, 1Stanford University, Palo Alto, CA, 2NIHR Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 3AbbVie Inc., North Chicago, IL, 4Analysis Group Inc., New York, NY, 5Rheumatology and Immunotherapy Center, Franklin, WI

    Background/Purpose: Upadacitinib (UPA) is a selective JAK-1 inhibitor with demonstrated patient-reported benefits in the treatment of active rheumatoid arthritis (RA).1,2 The objective of this analysis…
  • Abstract Number: 2869 • 2018 ACR/ARHP Annual Meeting

    Incorporation of Patient Reported Outcomes Data in the Care of US Veterans with Rheumatoid Arthritis: A Randomized, Controlled Trial

    Michael R Bubb1, Reuben Judd1 and Ann D Chauffe2, 1Medicine, Malcom Randall VAMC, Gainesville, FL, 2Rheumatology Clinic of Opelousas, Opelousas, LA

    Background/Purpose: Quantitative disease activity measures are required to implement a treat-to-target algorithm for the treatment of rheumatoid arthritis (RA). Available measures based on patient-derived data…
  • Abstract Number: 2249 • 2017 ACR/ARHP Annual Meeting

    Influence of Large-Joint Involvement on Patient-Physician Discordance in Global Assessment of Rheumatoid Arthritis Disease Activity Analyzed By Novel Joint Index

    Tetsuji Sawada1, Mayu Tago1, Susumu Nishiyama2, Koichiro Tahara1, Eri Kato3, Hiroaki Mori1, Haeru Hayashi1, Jinju Nishino4, Toshihiro Matsui5 and Shigeto Tohma6, 1Rheumatology, Tokyo Medical University, Tokyo, Japan, 2Rheumatic Disease Center, Kurashiki Medical Center, Okayama, Japan, 3Rheumatology, Tokyo Medical University, Shinjuku Tokyo, Japan, 4Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, 5Department of Lifetime Clinical Immunology Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, 6Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan

    Background/Purpose: The discordance between patient global assessment (PGA) and physician global assessment (PhGA) of rheumatoid arthritis (RA) disease activity may be problematic in clinical practice.…
  • Abstract Number: 133 • 2017 ACR/ARHP Annual Meeting

    Impact of the Five Components of the Euroqol 5-Dimensions Instrument on Healthcare and Work-Loss Costs in Rheumatoid Arthritis: Observational Data from Southern Sweden

    Anders Gülfe1, Tor Olofsson1, Jonas K Söderling2, Martin Neovius2 and Johan K Wallman1, 1Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden, 2Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Healthcare and work-loss costs are markedly higher in RA patients than in the general population. The EuroQol 5-Dimensions (EQ-5D) instrument, commonly applied to measure…
  • Abstract Number: 352 • 2017 ACR/ARHP Annual Meeting

    Psychometric Features of a New Methotrexate (MTX)-Specific Adherence Tool for Use in the Management of Patients with Rheumatoid Arthritis (RA): Preliminary Results from an Online Patient Community

    Elodie de Bock1, Corrado Bernasconi2, Tan P. Pham1, Ana Maria Rodriguez3, Khaled Sarsour4, J. Michael Nebesky2 and Christine de la Loge1, 1Mapi, Lyon, France, 2F. Hoffmann-La Roche, Basel, Switzerland, 3Patients Like Me (PLM), Cambridge, MA, 4Genentech, South San Francisco, CA

    Background/Purpose: F. Hoffmann-La Roche Ltd. and Mapi collaborated to develop a medication adherence measure among RA patients taking MTX—the Methotrexate Experience Questionnaire (MEQ). The MEQ…
  • Abstract Number: 501 • 2017 ACR/ARHP Annual Meeting

    Patient-Reported Outcomes of Long-Term Upadacitinib Use in Patients with Rheumatoid Arthritis: Interim Analysis Results of a Phase 2, Open-Label Extension Study

    Vibeke Strand1, Namita Tundia2 and Alan Friedman2, 1Stanford University, Palo Alto, CA, 2AbbVie Inc., North Chicago, IL

    Background/Purpose: Janus kinase (JAK) inhibitors are being evaluated for treatment of active rheumatoid arthritis (RA). The efficacy of upadacitinib (UPA), a selective JAK inhibitor, in…
  • Abstract Number: 510 • 2017 ACR/ARHP Annual Meeting

    Association between Clinical Response and Normalization of Patient-Reported Outcome Measures in Rheumatoid Arthritis: Post-Hoc Analysis from Two Phase 2b Filgotinib Studies

    Mark C. Genovese1, Annegret Van der Aa2, Corinne Jamoul2, Chantal Tasset2, Pille Harrison2, René Westhovens3 and Arthur Kavanaugh4, 1Stanford University Medical Center, Palo Alto, CA, 2Galapagos NV, Mechelen, Belgium, 3University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, 4Medicine, University of California, San Diego, La Jolla, CA

    Background/Purpose: Filgotinib (GLPG0634, GS-6034) is an oral, selective JAK1 inhibitor that has demonstrated safety and efficacy data in two 24-week placebo-controlled phase 2B studies as…
  • Abstract Number: 455 • 2016 ACR/ARHP Annual Meeting

    Validity, Reliability and Sensitivity to Change of Four Different Patient-Reported Outcomes (PROs) to Measure the Domains Pain, Fatigue, Experienced Disease Activity and General Well-Being in Patients with Rheumatoid Arthritis

    Lisanne Renskers1, Piet L.C.M. van Riel2,3 and Ron J.J.C. van Uden1, 1IQ healthcare, Radboud university medical center, Radboud Institute for Health Sciences, IQ healthcare, Nijmegen, Netherlands, 2Radboud university medical center, Radboud Institute for Health Sciences, IQ healthcare, Nijmegen, Netherlands, 3Bernhoven, Department of Rheumatology, Uden, Netherlands

    Background/Purpose: With Patient-Reported Outcomes (PROs), the patient's perspective can be assessed. Several forms can be used; Verbal Rating Scale (VRS), Numerical Rating Scale (NRS), Visual…
  • Abstract Number: 611 • 2016 ACR/ARHP Annual Meeting

    Analysis of a German Subpopulation with Active Rheumatoid Arthritis Treated with Golimumab As Add-on Therapy to Disease-Modifying Antirheumatic Drugs

    Hendrik Schulze-Koops1, Jürgen Wollenhaupt2, Marita Winnemöller3, Ines Klaudius3 and Helena Löffler3, 1Division of Rheumatology, Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, 2Schön Klinik Hamburg-Eilbek, Hamburg, Germany, 3Medical Affairs, MSD Sharp & Dohme GmbH, Haar, Germany

    Background/Purpose: In previous clinical studies the human monoclonal TNFα-antibody golimumab (GLM) showed a good clinical response and a favorable benefit:risk profile in the treatment of…
  • Abstract Number: 2730 • 2015 ACR/ARHP Annual Meeting

    Patient-Reported Outcomes from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs

    Paul Emery1, Carol L. Gaich2, Amy M. DeLozier3, Stephanie de Bono2,4, Jiajun Liu2, Cecile Chang2 and Maxime Dougados5, 1Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, 2Eli Lilly and Company, Indianapolis, IN, 3Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 4Eli Lilly and Company, Cookham, United Kingdom, 5Paris-Descartes University, Paris, France

    Background/Purpose: Baricitinib (bari) is an oral Janus kinase (JAK) 1 /JAK2 selective inhibitor, representing a potentially effective treatment for patients with moderately to severely active rheumatoid…
  • Abstract Number: 2642 • 2015 ACR/ARHP Annual Meeting

    Patient Reported Outcome Assessment of Rheumatoid Arthritis Patients Experience with IV Administered Biologic Therapy

    Norman B. Gaylis1, Joanne Sagliani1, Danny Tuccitto2, Shawn Black3, Kehzen Tang4, Raphael Dehoratius3,5 and Dennis Parenti3, 1Arthritis & Rheumatic Disease Specialties, Aventura, FL, 2AARDS Research, Inc, Aventura, FL, 3Janssen Scientific Affairs, LLC, Horsham, PA, 4Janssen Research & Development, LLC, Spring House, PA, 5Kimmel School of Medicine, Thomas Jefferson University, Philadelphia, PA

    Background/Purpose: Patient-reported outcomes (PRO) are used to assess patient related benefit in clinical trials. Rheumatoid arthritis (RA) patients are equally receptive to intravenous (IV) or…
  • Abstract Number: 2624 • 2015 ACR/ARHP Annual Meeting

    Preliminary Content Validation of the Patient Reported Outcomes Measurement Information System (PROMIS) Short Forms in People Living with Rheumatoid Arthritis

    Anna Kristina Gutierrez1, Michelle Jones2, Susan J. Bartlett1,3,4 and Clifton O. Bingham III2, 1Division of Rheumatology, Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, 4Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada

    Background/Purpose: The process of patient reported outcome (PRO) validation requires demonstration that the concept being measured and the patient experience of the corresponding symptom or…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences